1. Signaling Pathways
  2. MAPK/ERK Pathway
  3. Raf
  4. BRaf Inhibitors

BRaf Inhibitors

BRaf

c-Raf

Raf

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform BRaf together.

Please try each isoform separately.

BRaf Specific Inhibitors
Product Name BRaf c-Raf BRaf Selectivity Purity
Doramapimod
B-Raf, IC50: 83.4 nM
  Selective Inhibitor 99.88%
PLX-4720
B-RafV600E, IC50: 13 nM
B-Raf, IC50: 160 nM
  Selective Inhibitor 99.88%
GDC-0879
B-Raf, IC50: 0.13 nM
  Selective Inhibitor 99.94%
SB-590885
B-Raf, Ki: 0.16 nM
c-Raf, Ki: 1.72 nM
Selective Inhibitor 99.56%
Lifirafenib
BRafV600E, IC50: 23 nM
  Selective Inhibitor 98.02%
PLX7904
BRafV600E, IC50: 5 nM (in mutant RAS expressing cells)
  Selective Inhibitor 98.80%
BI-882370
Braf, IC50: 0.6 nM
BRafV600E, IC50: 0.4 nM
c-Raf, IC50: 0.8 nM
Selective Inhibitor 99.16%
PROTAC B-Raf degrader 1
B-Raf
  Selective Inhibitor 99.18%
B-Raf IN 1
B-Raf, IC50: 24 nM
  Selective Inhibitor 98.08%
HG6-64-1
B-RafV600E, IC50: 0.09 μM (in Ba/F3 cells)
  Selective Inhibitor ≥98.0%
BRAF inhibitor
B-Raf
  Selective Inhibitor 98.61%
LUT014
B-Raf, IC50: 11.7 nM
  Selective Inhibitor 97.19%
L-779450
B-Raf, Kd: 2.4 nM
  Selective Inhibitor 98.75%
RAF mutant-IN-1
B-RafV600E, IC50: 30 nM
BRAFWT, IC50: 392 nM
C-RAF 340D/Y341D, IC50: 21 nM
Selective Inhibitor
Sorafenib
Braf, IC50: 22 nM
BrafV599E, IC50: 38 nM
Raf-1, IC50: 6 nM
Pan Inhibitor 99.92%
Vemurafenib
B-RafV600E, IC50: 31 nM
c-Raf-1, IC50: 48 nM
Pan Inhibitor 99.80%
Regorafenib
BRafV600E, IC50: 19 nM
Braf, IC50: 28 nM
Raf-1, IC50: 2.5 nM
Pan Inhibitor ≥99.0%
Dabrafenib
BRafV600E, IC50: 0.6 nM
CRAF, IC50: 5 nM
Pan Inhibitor ≥95.0%
Sorafenib Tosylate
Braf, IC50: 22 nM
BrafV599E, IC50: 38 nM
Raf-1, IC50: 6 nM
Pan Inhibitor ≥98.0%
LY3009120
BRafV600E, IC50: 5.8 nM
Braf, IC50: 9.1 nM
CRAF, IC50: 15 nM
Pan Inhibitor 99.01%
Dabrafenib Mesylate
BRafV600E, IC50: 0.6 nM
CRAF, IC50: 5 nM
Pan Inhibitor 99.94%
LXH254
Braf
c-Raf
Pan Inhibitor 99.78%
Ro 5126766
BRafV600E, IC50: 8.2 nM
Braf, IC50: 190 nM
CRAF, IC50: 56 nM
Pan Inhibitor 98.27%
AZ 628
B-Raf, IC50: 105 nM
B-RafV600E, IC50: 34 nM
c-Raf-1, IC50: 29 nM
Pan Inhibitor 99.86%
Belvarafenib
BRafV600E, IC50: 7 nM
B-Raf, IC50: 56 nM
CRAF, IC50: 5 nM
Pan Inhibitor 98.05%
Regorafenib Hydrochloride
BRafV600E, IC50: 19 nM
Braf, IC50: 28 nM
Raf-1, IC50: 2.5 nM
Pan Inhibitor ≥98.0%
RAF709
Braf, IC50: 0.4 nM
CRAF, IC50: 0.5 nM
Pan Inhibitor 99.91%
Regorafenib monohydrate
BRafV600E, IC50: 19 nM
Braf, IC50: 28 nM
Raf-1, IC50: 2.5 nM
Pan Inhibitor 99.96%
CCT196969
BRafV600E, IC50: 0.04 μM
Braf, IC50: 0.1 μM
CRAF, IC50: 0.01 μM
Pan Inhibitor 99.04%
Agerafenib
Braf, Kd: 36 nM
BRafV600E, Kd: 14 nM
CRAF, Kd: 39 nM
Pan Inhibitor 99.53%
Raf inhibitor 1
B-Raf, Ki: 1 nM
B-RafV600E, Ki: 1 nM
c-Raf, Ki: 0.3 nM
Pan Inhibitor 98.05%
AZ304
BRafV600E, IC50: 38 nM
BRAFWT, IC50: 79 nM
CRAF, IC50: 68 nM
Pan Inhibitor 99.39%
KG5
B-Raf
c-Raf
Pan Inhibitor
Agerafenib hydrochloride
BRafV600E, Kd: 14 nM
Braf, Kd: 36 nM
CRAF, Kd: 39 nM
Pan Inhibitor
Raf inhibitor 1 dihydrochloride
B-Raf, Ki: 1 nM
B-RafV600E, Ki: 1 nM
c-Raf, Ki: 0.3 nM
Pan Inhibitor